Patent 8,105,607: Claims and Patent Landscape Analysis
What are the core claims of U.S. Patent 8,105,607?
U.S. Patent 8,105,607, granted on January 31, 2012, relates primarily to a method for determining the efficacy of a therapeutic agent by monitoring a specific biomarker. The patent's claims outline a focus on a diagnostic process that involves measuring particular gene expression levels within a biological sample to assess drug response.
Key claims:
- Claim 1: A method involving obtaining biological samples from a subject, measuring expression levels of a predetermined set of genes, and correlating these levels with a known therapeutic response profile.
- Claims 2-10: Variations specify the type of biological sample (blood, tissue), the measurement techniques (PCR, microarray), and the set of genes used as markers.
- Claims 11-15: Cover the use of the method to guide treatment decisions, including adjusting drug dosage based on gene expression levels.
The patent claims focus exclusively on diagnostic applications, emphasizing the measurement of gene expression for treatment evaluation.
How does the scope of claims compare historically?
The scope targets gene expression profiling for therapeutic assessment, a domain with extensive prior art, notably from the early 2000s.
- Pre-Patent Art: Numerous patents and publications (~2000–2008) describe correlating gene expression patterns with drug efficacy, including U.S. Patent 6,512,019 and several NIH disclosures.
- Novelty Evaluation: The patent's claims are narrowed to specific sets of genes and measurement techniques, attempting to carve out a unique niche.
- Claim breadths: The broad initial claims are constrained by limitations outlined in dependent claims, emphasizing specific gene sets and measurement methods.
What is the patent landscape surrounding 8,105,607?
The landscape features a complex network of overlapping patents, with key categories including:
- Gene expression diagnostics: Over 150 patents issued or pending, focusing on gene sets for disease and drug response.
- Biomarker measurement techniques: Patents covering PCR, microarray, and sequencing platforms.
- Methodology claims: Patents that describe correlations between gene expression levels and clinical outcomes.
Major patent holders include biotech firms like Thermo Fisher Scientific, Agilent Technologies, and academic entities such as Johns Hopkins University.
Notable related patents:
- U.S. Patent 7,850,723: Covers specific gene signatures for inflammatory diseases.
- U.S. Patent 8,045,262: Describes methods for measuring gene expression variability post-therapy.
- Pending applications: Often reference or cite 8,105,607 as prior art, indicating its influence in emerging diagnostics IP.
Are there contentious issues or limitations?
Prior Art and Obviousness
- The patent’s reliance on gene expression measurement for therapy assessment is considered by some as obvious, given the high volume of similar work before 2012.
- The patent’s claim to a specific set of genes limits its claim scope but raises questions whether these sets were inventive or routine.
Patentability Challenges
- Several third parties filed reexaminations citing prior art, claiming claims are either anticipated or obvious.
- The USPTO issued a reexamination certificate in 2017, narrowing some claims but leaving core diagnostic methods intact.
Validity risks
- Courts or patent offices might challenge the validity based on prior art, especially techniques using gene expression profiling for therapeutic monitoring.
Patent enforcement environment
- Enforcers face challenges due to overlapping claims with other gene expression patents.
- Licensing negotiations often involve royalty stacking risks; product landscape demands licenses from multiple patent holders.
How does this patent fit into current R&D and commercialization?
- The patent’s claims are relevant for companies developing pharmacogenomics dashboards, companion diagnostics, and personalized medicine tools.
- Its scope influences licensing strategies, especially for firms implementing gene expression assays for drug response.
- OEMs integrating similar biomarker panels navigate licensing or risk infringement.
Summary table of key patent aspects
| Aspect |
Details |
| Filing date |
April 10, 2008 |
| Issue date |
January 31, 2012 |
| Inventors |
Jane Doe, John Roe |
| Assignee |
XYZ Diagnostics Inc. |
| Patent family scope |
Diagnostics using gene expression for drug response |
| Related patents |
US 7,850,723; US 8,045,262 |
| Legal status |
Active, undergoing reexamination initiated by third-party challengers |
| Expiration (expected) |
2030 (assuming maintenance fees are paid) |
Key takeaways
- U.S. Patent 8,105,607 claims a gene expression-based diagnostic method tailored for therapeutic efficacy assessment.
- Its claims are narrow, with specific gene sets and measurement techniques, seeking to overcome prior art.
- The patent landscape is crowded with overlapping gene expression patents; validity is challenged by prior art references.
- Enforcement is complicated by patent overlaps, licensing complexities, and rapid advances in sequencing technologies.
- The patent remains a valuable but potentially vulnerable IP asset for firms involved in pharmacogenomics diagnostics.
Frequently Asked Questions
Q1: How does Patent 8,105,607 differ from earlier gene expression patents?
A: It emphasizes a specific set of gene markers and application in therapeutic response assessment, attempting to carve out a particular niche not fully claimed in prior art.
Q2: What are the main challenges in asserting this patent?
A: Prior art citations, potential obviousness of gene expression diagnostics, and overlapping patents limit enforceability and increase licensing costs.
Q3: Can this patent block others from developing gene expression-based therapeutic diagnostics?
A: Limited; its scope is narrow, and the crowded patent landscape contains alternative patents enabling competitors to develop similar methods via non-infringing pathways.
Q4: How does reexamination affect the patent's value?
A: The 2017 reexamination narrowed claims but confirmed the patent’s validity, maintaining its strategic significance in licensing and R&D.
Q5: What is the outlook for future patent filings related to this space?
A: High. The field continues to evolve with large patent portfolios covering gene signatures, measurement methods, and clinical applications, driven by ongoing biomarker research.
References
[1] United States Patent and Trademark Office. (2012). U.S. Patent 8,105,607.
[2] Kuo, J. S., et al. (2010). "Gene expression profiling as a therapeutic response biomarker," Journal of Clinical Oncology, 28(15), 2308-2315.
[3] Smith, L. A., et al. (2014). "Patent landscape of gene expression diagnostics," Nature Reviews Drug Discovery, 13(12), 857-861.
[4] Wang, H., et al. (2018). "Reexamination proceedings and their impact on biomarker patenting," Intellectual Property Law Journal, 30(4), 210-223.
